Inovio says COVID-19 vaccine candidate safe, effective in clinical trial
Send a link to a friend
[May 10, 2021]
(Reuters) - Inovio Pharmaceuticals Inc said
on Monday its COVID-19 vaccine candidate was safe, well-tolerated and
produced immune response against the coronavirus in all tested age
groups as part of a mid-stage clinical trial.
|
|
 The
company's shares were up 7% at $7.34 before the bell.
The trial enrolled about 400 participants aged 18 years and older at
16 U.S. sites. The company said it has selected 2 mg dose for the
phase 3 segment of the trial.
Inovio plans to file preliminary mid-stage results with the U.S.
Food and Drug Administration (FDA).
Last month, the company said the U.S. government pulled the funding
for a late-stage study testing its vaccine candidate and it would
now conduct the trial largely outside the country.
[to top of second column] |
In September, the FDA put the phase 3 portion of the mid-to-late
stage trial on hold for more information on the device used to
inject the shot.
(Reporting by Manojna Maddipatla and Dania Nadeem in Bengaluru;
Editing by Bernard Orr and Shounak Dasgupta)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
